Hims & Hers Q4 2024 Earnings Report
Key Takeaways
Hims & Hers Health, Inc. delivered strong Q4 2024 results with a 95% year-over-year revenue growth to $481.1 million. The company also reported a net income of $26.0 million, significantly higher than the prior year’s $1.2 million. Adjusted EBITDA reached $54.1 million, up from $20.6 million in Q4 2023, and free cash flow rose to $59.5 million from $10.8 million a year ago.
Revenue grew 95% year-over-year to $481.1 million in Q4 2024.
Net income surged to $26.0 million from $1.2 million in Q4 2023.
Adjusted EBITDA rose to $54.1 million, a 163% increase year-over-year.
Subscribers increased 45% year-over-year, reaching 2.2 million.
Hims & Hers Revenue
Hims & Hers EPS
Hims & Hers Revenue by Segment
Forward Guidance
Hims & Hers expects continued revenue and profitability growth in 2025, with full-year revenue projected between $2.3 billion and $2.4 billion and Adjusted EBITDA between $270 million and $320 million.
Positive Outlook
- Revenue guidance for FY 2025 set between $2.3 billion and $2.4 billion.
- Adjusted EBITDA expected to increase to a range of $270 million to $320 million.
- Continued subscriber growth anticipated, expanding its market reach.
- Expansion into new healthcare segments supporting growth outlook.
- Strong cash flow position supports investment in further innovation.
Challenges Ahead
- Gross margin declined from 83% in Q4 2023 to 77% in Q4 2024.
- Higher marketing expenses impacting operating profit margins.
- Competitive landscape in digital health remains challenging.
- Uncertainty in regulatory environments could impact growth strategies.
- Macroeconomic conditions may influence consumer healthcare spending.
Revenue & Expenses
Visualization of income flow from segment revenue to net income